Anesthesia management for cesarean section during coronavirus disease 2019 epidemic

Use of SARS-CoV-2-infected deceased organ donors: Should we always "just say no?"

Introdução: A doença Coronavírus 2019 (COVID-19), causadora do Síndrome Respiratório Agudo Severo 2 (SARS-CoV-2), foi reportada pela primeira vez, em Wuhan (China) e declarada como pandemia em março de 2020. Até à data, são limitadas as informações clínicas, abordagem anestésica e prognóstico das grávidas infetadas. O objetivo deste estudo, foi a caraterização da experiência clínica e segurança das técnicas anestésicas na abordagem à grávida infetada e submetida a técnicas anestésicas/analgésicas para trabalho de parto ou cesariana. Métodos: Foi realizado um estudo retrospetivo incluindo todas as parturientes infetadas admitias no Centro Hospitalar Universitário de São João. Dados sobre o contexto demográfico, epidemiológico, resultados dos estudos laboratoriais e imagem radiológica realizados à admissão foram colhidos. Analisou-se os procedimentos anestésicos/analgésicos realizados, bem como dados relacionados com a cirurgia, puérpera e neonato. Resultados: Incluiu-se neste estudo 15 parturientes infetadas com SARS-CoV-2. Sintomas e características clínicas foram semelhantes às reportadas na população adulta não obstétrica. O parto vaginal e anestesia/analgesia do neuroeixo foi realizada na maioria dos casos, em contraste com os estudos previamente publicados. Das parturientes sob analgesia epidural, a maioria permaneceu com Patient Controlled Epidural Analgesia até ao parto. Apenas em um caso foi necessário anestesia geral e intubação traqueal. Todos os recém-nascidos foram negativos para SARS-CoV-2. Não foram reportados complicações ou eventos críticos maternos ou nos recém-nascidos. Conclusão: Neste estudo, as técnicas regionais para anestesia/analgesia para trabalho de parto foram a primeira linha na abordagem anestésica das parturientes infetadas. A segurança e eficácia destes procedimentos foram verificadas sem complicações maternas ou neonatais.

Coronavirus disease 2019 (COVID-19) is caused by a novel strain of coronavirus, designated as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It has caused a global pandemic rapidly s...

Targeting the Gut Microbiota in Coronavirus Disease 2019: Hype or Hope?

COVID-19: What do we know?

Harnessing innate immunity to eliminate SARS-CoV-2 and ameliorate COVID-19 disease.

Does COVID-19 cause pre-eclampsia?

Transmission of infection from non-isolated patients with COVID-19 to healthcare workers

The coronavirus disease 2019 (COVID-19) pandemic constitutes a global health emergency. Currently, there are no completely effective therapeutic medications for the management of this outbreak. The cytokine storm is a hyperinflammatory medical condition due to excessive and uncontrolled release of pro-inflammatory cytokines in patients suffering from severe COVID-19, leading to the development of acute respiratory distress syndrome (ARDS) and multiple organ dysfunction syndrome (MODS) and even mortality. Understanding the pathophysiology of COVID-19 can be helpful for the treatment of patients. Evidence suggests that the levels of tumor necrosis factor alpha (TNF-α) and interleukin (IL)-1 and IL-6 are dramatically different between mild and severe patients, so they may be important contributors to the cytokine storm. Several serum markers can be predictors for the cytokine storm. This review discusses the cytokines involved in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, focusing on interferons (IFNs) and ILs, and whether they can be used in COVID-19 treatment. Moreover, we highlight several microRNAs that are involved in these cytokines and their role in the cytokine storm caused by COVID-19.

COVID-19 in a 26-week preterm neonate

Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia.

Editorial: Coronavirus disease 2019 (COVID-19) - advances in epidemiology, diagnostics, treatments, host-directed therapies, pathogenesis, vaccines, and ongoing challenges.

Following its emergence in December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused what rapidly became a global pandemic. The precise origin and subsequent path of transmission have not yet been established-but like the other novel coronaviruses that it closely resembles, it appears to have evolved naturally in a bat host. The disease caused by SARS-CoV-2 infection, designated as coronavirus disease 2019 (COVID-19), ranges from asymptomatic, to mild self-limited illness, to progressive pneumonia, respiratory compromise, multiorgan failure, and death. In addition, a hyperinflammatory disease state occurs in a subset of patients, and may be seen either during acute infection or following recovery. The search for effective pharmacological management of COVID-19 continues, but several promising candidates have been identified, including the viral nucleoside analog remdesivir. However, despite the existence of literally thousands of clinical trials, the management of COVID-19 remains challenging, and the development of an optimal, evidence-based therapeutic approach is ongoing. The impact of SARS-CoV-2 and COVID-19 on the biobanking world is evolving and profound-in particular, it is likely that many of mysteries surrounding COVID-19 will be solved via the availability of high-quality, large-scale collection, storage, and analysis of patient specimens. The purpose of this review article is therefore to provide a rapid, comprehensive, and relevant overview and primer on SARS-CoV-2 and COVID-19, with attention to the epidemiology, virology, transmission, clinical features, and major therapeutic options currently existent.

COVID-19 vasculitis and novel vasculitis mimics.

AGA Rapid Recommendations for Gastrointestinal Procedures During the COVID-19 Pandemic